Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

1454GCC: Anti-PD-1 (MK-3475) and IMiD (Pomalidomide) Combination Immunotherapy in Relapsed/Refractory Multiple Myeloma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02289222
Recruitment Status : Terminated (Due to the inclusion of an IMid in combination with pembrolizumab, Study Sponsor terminated the study.)
First Posted : November 13, 2014
Results First Posted : August 1, 2018
Last Update Posted : August 1, 2018
Sponsor:
Collaborator:
Merck Sharp & Dohme Corp.
Information provided by (Responsible Party):
Ashraf Badros, University of Maryland, College Park

Brief Summary:
This is an open label trial of Anti PD1/MD-3475, Pomalidomide and dexamethasone. The study will use standard (FDA approved) doses for both pomalidomide and dexamethasone. The experimental drug Anti PD-1 (MK 3475) given on days 1 and 14.

Condition or disease Intervention/treatment Phase
Multiple Myeloma Drug: MK-3475 Drug: Pomalidomide Drug: Dexamethasone Phase 1 Phase 2

Detailed Description:
This phase I/II study is focused on patients with relapsed or refractory multiple myeloma. MK-3475 will be given as an intravenous infusion at every 2 weeks. Treatment will be administered on an outpatient basis.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 48 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: 1454GCC: Phase I/II Anti-PD-1 (MK-3475) and IMiD (Pomalidomide) Combination Immunotherapy in Relapsed/Refractory Multiple Myeloma
Actual Study Start Date : December 30, 2014
Actual Primary Completion Date : August 7, 2017
Actual Study Completion Date : August 7, 2017


Arm Intervention/treatment
Experimental: Pomalidomide, Dexamethasone & MK-3475
Pomalidomide is given at standard dose of 4 mg daily orally for 21 days and dexamethasone is given at 40 mg orally weekly. MK3475 will be given as an intravenous infusion at 200 mg every 2 weeks (days 1 and 14).
Drug: MK-3475
Anti PD-1 (MD 3475) will be given as an intravenous infusion at 200 mg every 2 weeks.
Other Name: Generic name: Pembrolizumab - Trade name: Keytruda

Drug: Pomalidomide
Pomalidomide is given at standard dose of 4 mg daily orally for 21 days
Other Name: Pomalyst, CC-4047, Actimid

Drug: Dexamethasone
Dexamethasone is given at 40 mg orally weekly
Other Name: Decadron




Primary Outcome Measures :
  1. The Number of Participants With Adverse Events [ Time Frame: 24 month ]
    Establish the safety and tolerability of Pomalidomide and Dexamethasone in combination with MK-3475


Secondary Outcome Measures :
  1. PD-LI Expression On Myeloma Cells [ Time Frame: Tissue sample collection will take place before starting study therapy with MK-3475 at baseline and again at time of relapse as defined by the International Myeloma Working Group Response Criteria (Average of up to 24months) ]
    The identification of a biomarker for response by evaluating PD-1/PDL-1 expression in patients' bone marrow aspirate samples will be analyzed in order to help select patients for future anti-PD-1 therapy. The main exploratory biomarker analysis was to examine potential correlation between expression of PD-1 on T cells and PD-L1 on myeloma cells with clinical outcome using the following parameters: response rate focusing on responses ≥ very good partial response (VGPR) and PFS. SAS software (v.9.4; SAS Institute, Inc, Cary, NC) was used for statistical analyses.

  2. Time to Progression Free Survival (PFS) [ Time Frame: PFS assessments will take place after starting study therapy with MD-3475 and will continue until the start of a new anti-neoplastic therapy, disease progression, death, or the end of study up to an average of 24 months. ]
    PFS will be measured in all participants. Survival and PFS functions were estimated using the Kaplan-Meier method. The Cox regression model was used to assess the following plausible risk factors for OS and PFS: age, isotype, number of cycles of therapy, and cytogenetic profile.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Confirmed diagnosis of relapsed and/or refractory MM according to International Myeloma Working Group guidelines (2003)
  2. Received two lines of prior therapy that includes an IMiD (lenalidomide or thalidomide) and a proteasome inhibitor (bortezomib and/or carfilzomib) (used either separately or in combination). (a). Prior pomalidomide therapy is permitted, provided the patient achieved at least a partial remission and had not progressed for 3 months after stopping therapy.
  3. Measureable disease as defined by the protocol (assessed within 28 days prior to registration).
  4. Be willing and able to provide written informed consent/assent for the trial.
  5. Be over 18 years of age on day of signing informed consent.
  6. Have a performance status of 2 on the ECOG Performance Scale.
  7. Demonstrate adequate organ function as defined by the protocol.
  8. Female subject of childbearing potential should have a negative serum pregnancy within 72 hours prior to receiving the first dose of study drug.
  9. Male subjects should agree to use an adequate method of contraception.

Exclusion Criteria:

  1. Is currently participating in or has participated in a study of an investigational agent or using an investigational device within 4 weeks of the first dose of treatment.
  2. Has a diagnosis of immunodeficiency (HIV) or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatment.
  3. Has had a prior monoclonal antibody within 4 weeks prior to study Day 1 or who has not recovered (i.e., ≤ Grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlier.
  4. Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study Day 1 or who has not recovered (i.e., ≤ Grade 1 or at baseline) from adverse events due to a previously administered agent. (Subjects with ≤ Grade 2 neuropathy are an exception to this criterion and may qualify for the study.)
  5. Has a known additional malignancy that is progressing or requires active treatment. Exceptions include basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or situ cervical cancer that has undergone potentially curative therapy.
  6. Has known active central nervous system disease and/or carcinomatous meningitis.
  7. Has an active autoimmune disease requiring systemic treatment within the past 3 months or a documented history of clinically severe autoimmune disease, or a syndrome that requires systemic steroids or immunosuppressive agents.
  8. Has evidence of interstitial lung disease or active, non-infectious pneumonitis.
  9. Has an active infection requiring systemic therapy.
  10. Has a history or current evidence of any condition, therapy, or lab abnormality that might confound the results of the trial, interfere with the subject's participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the treating investigator.
  11. Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.
  12. Pregnant or breastfeeding, or expecting to conceive or father children during study participation.
  13. Has received prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-Cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) antibody as per the protocol.
  14. has known active Hepatitis B or Hepatitis C.
  15. Has a known history of Human Immunodeficiency Virus (HIV) (HIV 1/2 antibodies)
  16. Has received a live vaccine within 30 days prior to the first dose of trial treatment.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02289222


Locations
Layout table for location information
United States, Maryland
Greenebaum Cancer Center at University of Maryland Medical Center
Baltimore, Maryland, United States, 21201-1592
Sponsors and Collaborators
Ashraf Badros
Merck Sharp & Dohme Corp.
Investigators
Layout table for investigator information
Principal Investigator: Ashraf Z Badros, M.B.,Ch.B University of Maryland Greenebaum Cancer Center
  Study Documents (Full-Text)

Documents provided by Ashraf Badros, University of Maryland, College Park:

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Ashraf Badros, Sponsor-Investigator, University of Maryland, College Park
ClinicalTrials.gov Identifier: NCT02289222     History of Changes
Other Study ID Numbers: HP-00061522; GCC1454
First Posted: November 13, 2014    Key Record Dates
Results First Posted: August 1, 2018
Last Update Posted: August 1, 2018
Last Verified: July 2018
Keywords provided by Ashraf Badros, University of Maryland, College Park:
Relapsed/Refractory
MK-3475 & Pomalidomide
Immunotherapy
Additional relevant MeSH terms:
Layout table for MeSH terms
Multiple Myeloma
Neoplasms, Plasma Cell
Neoplasms by Histologic Type
Neoplasms
Hemostatic Disorders
Vascular Diseases
Cardiovascular Diseases
Paraproteinemias
Blood Protein Disorders
Hematologic Diseases
Hemorrhagic Disorders
Lymphoproliferative Disorders
Immunoproliferative Disorders
Immune System Diseases
Thalidomide
Dexamethasone
Dexamethasone acetate
Pembrolizumab
Pomalidomide
BB 1101
Anti-Inflammatory Agents
Antiemetics
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Gastrointestinal Agents
Glucocorticoids
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Antineoplastic Agents, Hormonal